TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03675958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Johnstone's Pressure Splint
Description: the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
Study: NCT02782897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Therapy
Description: Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard management
Description: Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard management
Description: Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
Study: NCT02526381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danlou Tablets
Description: Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongmai Yangxin Pills
Description: Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
Study: NCT03062800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100-200mg/d,oral ,qn

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: (500mg/m\^2) on day 1 of 21-days cycle,ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: (500mg/m\^2) on day 1 of 21-days cycle,ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: (75mg/m\^2) on day 1 of 21-days cycle, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: (75mg/m\^2) on day 1 of 21-days cycle, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: (AUC=5) on day 1 of 21-days cycle, ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: (AUC=5) on day 1 of 21-days cycle, ivgtt
Study: NCT02618330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retainer
Description: 24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retainer
Description: 24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
Study: NCT03361332

Intervention type: OTHER
Intervention: Behavioral and fMRI
Description: Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.

Intervention type: OTHER
Intervention: Behavioral and fMRI
Description: Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
Study: NCT04736316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early CCLAD
Description: Community-based client led antiretroviral therapy delivery groups.
Study: NCT02341573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experienced chinese herbal formulas
Description: At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leukotriene receptor antagonist and bronchial relaxant
Description: At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
Study: NCT00513422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate and chondroitin
Description: Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate
Description: Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules for glucosamine and chondroitin
Description: Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years.
Study: NCT00795691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-carbohydrate diet
Description: ketogenic low-carbohydrate diet in patients with type 2 diabetes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low-fat diet
Description: low-fat diet in patients with type 2 diabetes
Study: NCT03116165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified prolonged exposure therapy
Description: Participants will receive three sessions of modified prolonged exposure therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Participants will receive three sessions of supportive counselling and psychoeducation
Study: NCT00861497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: Flexible dosage: 20, 30, or 40 mg/day
Study: NCT02912286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional needle irrigation
Description: conventional side-vented syringe used to deliver irrigant in root canal treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive ultrasonic irrigation
Description: ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonic irrigation
Description: vibringe system is a sonic device that deliver and agitate the irrigant
Study: NCT00014534

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 6 mg sub Q

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 60 mg/sq m IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 50 mg/ sq m IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
Study: NCT02283216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noise sound stimulation (Tucker-Davis Technologies)
Description: Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body electrical stimulation (Digitimer device)
Description: Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation (Magstim)
Description: Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
Study: NCT00864500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate 0.05% lotion, single exposure
Description: A: Experimental Subjects received Alpharma USPD, Inc formulated products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobex TM 0.05% Lotion, single exposure
Description: B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
Study: NCT00273364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Therapy
Description: After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment with a conventional drug
Description: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
Study: NCT02023723

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy Drink
Description: 16oz energy drinks - 2 consumed within 60 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: 16oz energy drinks - 2 consumed within 60 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: 16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
Study: NCT04376645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Setback with maxillary impaction
Description: Occlusal bite force will be measured after surgery to correct vertical disproportions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular setback only
Description: Occlusal bite force will be measured after surgery without changing vertical disproportions.
Study: NCT03154619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% TR 987
Description: TR 987 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
Study: NCT01007461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide (Na2S) for Injection
Description: IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
Study: NCT01132521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
Study: NCT00445614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of trout on CVD risk markers and plasma proteome

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Effects of trout on CVD risk markers and plasma proteome

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of trout on CVD risk markers and plasma proteome
Study: NCT04535596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week long strength training exercises for knee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week long strength training exercises for knee
Study: NCT03040258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-E-PALS-Pilot
Description: Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
Study: NCT03132597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: six weeks of 2 hours class of mindfulness training and orientations for home training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: six weeks of 2 hours class of mindfulness training and orientations for home training
Study: NCT03318614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics M-63
Description: B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No probiotic intervention was given to the control group for three months.
Study: NCT03794765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Similar placebo infusion
Study: NCT01744444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
Study: NCT01837316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg
Description: First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: First strip: Inhalation powder of lactose
Study: NCT01332149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched with pregabalin
Description: Subject will take placebo matched with pregabalin twice a day.
Study: NCT01701466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aveeno cream
Description: Twice a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aveeno cream
Description: Twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamazine cream
Description: Twice a day, when there is dry desquamation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flamazine cream
Description: Twice a day, when there is dry desquamation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeoVIDERM cream
Description: Three times a day
Study: NCT00218062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Amphetamine 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Amphetamine 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02023723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Control
Description: 16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
Study: NCT02642991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phenacite
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenacite
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: contact lens
Study: NCT01853969

Intervention type: OTHER
Intervention: Typing assessment
Study: NCT03515681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
Study: NCT00123981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-Pump Coronary Artery Bypass Grafting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-Pump Coronary Artery Bypass Grafting
Study: NCT00422565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor, Medtronic
Description: Zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher, Cordis
Description: Sirolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte, Boston Scientific
Description: Paclitaxel-eluting stent
Study: NCT01088516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC
Description: Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
Study: NCT03085927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Music Engagement
Description: Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Storybooks
Description: Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
Study: NCT03475160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate vaginal suppositories
Description: Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal suppositories
Description: Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Uterine artery Doppler before treatment
Description: Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery Doppler before treatment
Description: Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Uterine artery Doppler after treatment
Description: Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery Doppler after treatment
Description: Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation